Inoperable pituitary tumours treated with <SUP>90</SUP>Y-DOTA-TATE – initial results

Grzegorz Kaminski; Norbert Szalus; Grzegorz Zielinski; Zbigniew Podgajny; Wojciech Zgliczynski; Anna Kasperlik-Zaluska; Joanna Cyperling-Kaminska; Eugeniusz Dziuk

OC8.5

Prev Next

Section Contents Cite

Endocrine Abstracts (2007) 14 OC8.5

ECE2007 Oral Communications Neuroendocrinology clinical (7 abstracts)

Inoperable pituitary tumours treated with ⁹⁰Y-DOTA-TATE – initial results

Grzegorz Kaminski ¹ , Norbert Szalus ¹ , Grzegorz Zielinski ¹ , Zbigniew Podgajny ¹ , Wojciech Zgliczynski ² , Anna Kasperlik-Zaluska ² , Joanna Cyperling-Kaminska ³ & Eugeniusz Dziuk ¹

Views

Author affiliations

¹Military Institute of Health Services, Warsaw, Poland; ²Medical Center of Postgraduate Education, Warsaw, Poland; ³LIM Medical Center, Warsaw, Poland.

Introduction: The patients with inoperable hormone - secreting pituitary tumours are treated with cold somatostatin analogues, but it is not always effective. DOTA-TATE preparation is a somatostatin analogue coupled with β (−) emitter ⁹⁰ Y. The efficacy of the treatment is based on excessive expression of somatostatin receptors (SSTR) in these tumours.

The aim of the study: To assess the feasibility of treatment of pituitary tumours with ⁹⁰Y-DOTA-TATE preparation.

Material and methods: ⁹⁰Y-DOTA-TATE preparation was used in 4 patients with inoperable tumour: 3 patients with acromegaly and 1 with the Nelson’s syndrome. The presence of SSTR was confirmed in scintigraphy with ^{99 m}Tc-HYNIC-TATE preparation earlier. Both radiopharmaceuticals are produced by POLATOM – Swierk/Poland. In 2 pts with acromegaly the dose was repeated twice. 1 pt with acromegaly and 1 pt with Nelson’s syndrome were treated with the ⁹⁰Y-DOTA-TATE four times (3.7 GBq per dose). The renal protection was provided by 10 hours infusion of 1000 ml 10% amino acids preparation with max. speed of 120 ml/h. The local Ethical Committee approval has been obtained before the study.

Results: There were no serious adverse events observed after ⁹⁰Y-DOTA-TATE treatment. An insignificant, transient decrease of thrombocytes and lymphocytes was noted. In patients with the Nelson’s syndrome the ACTH serum concentration decreased by 31%, in patients with acromegaly GH serum concentration decreased by about 30–40%, and clinical improvement was obtained.

Conclusions: ⁹⁰Y-DOTA-TATE radiopharmaceutic is feasible and promising in treatment of inoperable pituitary tumours.